TOPOTECAN Drug Patent Profile
✉ Email this page to a colleague
When do Topotecan patents expire, and when can generic versions of Topotecan launch?
Topotecan is a drug marketed by Sandoz Inc, Accord Hlthcare, Actavis Totowa, Dr Reddys Labs Ltd, Fresenius Kabi Usa, Meitheal, Mylan Labs Ltd, Novast Labs, Sagent Pharms, Sun Pharm Inds Ltd, Teyro Labs, Dash Pharms, and Hospira Inc. and is included in sixteen NDAs.
The generic ingredient in TOPOTECAN is topotecan hydrochloride. There are ten drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the topotecan hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Topotecan
A generic version of TOPOTECAN was approved as topotecan hydrochloride by FRESENIUS KABI USA on November 29th, 2010.
Summary for TOPOTECAN
US Patents: | 0 |
Applicants: | 13 |
NDAs: | 16 |
Raw Ingredient (Bulk) Api Vendors: | 93 |
Clinical Trials: | 434 |
Patent Applications: | 2,113 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TOPOTECAN |
What excipients (inactive ingredients) are in TOPOTECAN? | TOPOTECAN excipients list |
DailyMed Link: | TOPOTECAN at DailyMed |
Recent Clinical Trials for TOPOTECAN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Amgen | Phase 3 |
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Phase 2 |
Bristol-Myers Squibb | Phase 2 |